PTX prescient therapeutics limited

I agree, Logan. CellPryme-M is the one that has been under...

  1. 8,346 Posts.
    lightbulb Created with Sketch. 3672
    I agree, Logan. CellPryme-M is the one that has been under evaluation by prospective parties. In that context, it should garner an outcome before CellPryme-A in terms of a licensing deal. The latter was just brought up by me in context of Scotty mentioning PTX-200. Either way, the CP platform is still in the pipeline, albeit in the background, along with OmniCAR.

    Great to see James has a "Corporate Spotlight" interview happening on HC. The more interviews and presentations he does, the better he is getting. PTX-100 for CTCL is definitely the stepping stone to a much bigger market in the oncology space.
 
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)
Last
4.5¢
Change
0.001(2.27%)
Mkt cap ! $36.23M
Open High Low Value Volume
4.5¢ 4.6¢ 4.5¢ $6.007K 133.4K

Buyers (Bids)

No. Vol. Price($)
3 480817 4.5¢
 

Sellers (Offers)

Price($) Vol. No.
4.6¢ 48908 1
View Market Depth
Last trade - 16.10pm 26/06/2025 (20 minute delay) ?
PTX (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.